Fluorouracil/folinic acid - FivepHusion
Alternative Names: 5-fluorouracil/leucovorin; 5-FU/leucovorin; 5-FU/LV; Fluorodex; Fluorouracil/leucovorin; Folinic acid/5-fluorouracil; Leucovorin/5-fluorouracil; Leucovorin/5-FU; LV/5-FULatest Information Update: 02 Aug 2023
At a glance
- Originator University of Wollongong
- Developer Fivephusion
- Class Antineoplastics; Chemoprotectants; Chemosensitisers; Formyltetrahydrofolates; Pyrimidinones; Small molecules
- Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Jul 2023 FivepHusion enters into a clinical collaboration agreement with Allarity Therapeutics
- 31 Jul 2023 FivepHusion plans a phase Ib/IIa trial in Colorectal cancer (First line therapy, Inoperable/ Unresectable, Metastatic disease) in H2 2023
- 05 Oct 2020 Phase I/II trial is still ongoing for Solid tumours in Australia (FivepHusion Pipeline, October 2020)